According to a New York Times article, customers of 23andMe, a genetic data company, may be facing greater risks than they realize. The article suggests that the company’s current troubles may pale in comparison to the potential long-term threats that could affect the approximately 15 million people who have used 23andMe’s services if the company is unable to continue operating.
Founder and CEO Anne Wojcicki’s hope of reviving 23andMe seems to be fading with each passing day. The company, which was once valued at $6 billion when it went public in 2021, is now only valued at $150 million and is at risk of being delisted next month. Negative press coverage isn’t helping the situation either.
Despite the company’s claims to adhere to data regulations, there are concerns about what could happen if they are unable to do so in the near future. A Yale biomedical professor highlighted in the Times article points out that while hacked credit cards can be replaced, a compromised genome is irreversible. Additionally, advancements in genome analysis technology may lead to even more revealing information being uncovered.
Source link
This article was complied by AI and NOT reviewed by human. More information can be found in our Terms and Conditions.
